ObjectiveTo evaluate the safety and efficacy of segmentectomy for early stage non-small cell lung cancer. MethodsWe retrospectively analyzed the clinical data of 88 patients with pulmonary malignant or benign lung tumor who underwent segmentectomy in our hospital between January 2007 and December 2012. There were 45 male and 43 female patients. There were 29 patients in the segmentectomy group and 59 patients in the lobectomy group. Nonsmall cell lung cancer patients underwent segmentectomy were matched with non-small cell lung cancer patients who underwent lobectomy. Perioperative factors and tumor relative prognosis were analyzed. ResultsSegmentectomy were performed in 29 patients in our institution. Average operation time was 210 minutes. Intraoperative blood loss was 166 ml. Postoperative drainage was 2 147 ml. The average extubation duration was 6 days. No significant difference was found in operation time (P>0.999), intraoperative blood loss (P=0.207), postoperative drainage (P=0.946), extubation duration (P=0.804), and postoperative complication (P>0.999) between segmentectomy pulmonary benign disease and segmentectomy lung cancer groups. Compared with lobectomy, segmentectomy showed similar operation time (P=0.462), intraoperative blood loss (P=0.783), extubation duration (P=0.072), complication ratio (P>0.999), and postoperative recurrence/metastasis ratio (P=0.417). While the number of N1 lymph nodes (P=0.033) and N1 station (P=0.024) were fewer in the segmentectomy group than those in the lobectomy group. The overall survival rate (P=0.340) and disease free survival rate (P=0.373) were both comparable between the segmentectomy and the lobectomy group. ConclusionSegmentectomy could be an alternate of lobectomy for patients with selective pulmonary benign disease, and for some early stage non-small cell lung cancer patients with restricted pulmonary function.
ObjectiveTo identify prognostic factors for patients with non-small cell lung cancer (NSCLC) in pathologic stage ⅠA after operation. MethodsWe retrospectively analyzed the clinical data of 138 patients, who underwent surgical resection at our institution for stage ⅠA NSCLC. There were 81 males and 57 females with a median age of 61 years (ranged from 37 to 80 years). The in-hospital data and follow-up results were collected. Survival curve was generated by Kaplan-Meier method. Univariate and multivariate analyses of disease-free survival (DFS) were performed. ResultsThe follow-up time was from 9 to 90 months with a median of 59 months. During the follow-up, recurrence and metastasis occurred in 14 patients, local relapse in 8 patients, bone and ipsilateral lymph node metastasis occurred in one patient. Univariate analysis showed that DFS of patients was related with blood vessel or lymphatic invasion (P=0.017), poor histological differentiation (P=0.043), and tumor diameter ≥2 cm (P=0.017), respectively. Multivariate analysis demonstrated that tumor diameter ≥2 cm (P=0.026) and blood vessel or lymphatic invasion (P=0.011) were independent prognostic factors for DFS of stage ⅠA NSCLC patients after operation. ConclusionOur analyses indicate vessel involvement and the tumor diameter are independent indicators of DFS in patients with pathologic stage ⅠA NSCLC after operation.
ObjectiveTo evaluate the prognostic significance of postoperative metastasis in non-small cell lung cancer (NSCLC). MethodsWe retrospectively analyzed the clinical data of 94 patients who underwent curative lobectomy and pathologically diagnosed with NSCLC in our hospital between January 2005 and December 2011. There were 53 males and 41 females with a mean age of 62 (57-76) years. ResultsAmong 94 patients, metastasis occurred during late stage (more than 2 years postoperatively) in 49 (52.12%) patients. Single organ metastasis and multiple organ metastasis were found in 85 (90.43%) patients. The most popular metastatic site was lung (38/94,40.42%), and then bone (27/94,28.72%), and brain (24/94,25.53%). The overall survival (OS) rate of all included patients was 41.5%. The median survival time was 43 months and 29 months for the single metastasis and multiple metastasis groups respectively. There was a statistical difference in OS rate between the single metastasis and multiple metastasis groups (45.9% vs. 0.0%, P<0.001). The median survival time was 50 months and 32 months for early metastatic patients and late metastatic patients respectively. Statistical difference was found in OS rate between the single metastasis and multiple metastasis groups (53.3% vs. 30.6%, Cox P=0.130, Breslow P=0.014). Cox regression showed TNM stage (P=0.003) and single organ metastasis (P<0.001) were significant prognostic factors for NSCLC. ConclusionLung, bone, and brain were the most popular metastatic organs for postoperative NSCLC. The presence of multiple organ metastases can be identified as an independent poor prognostic factor in NSCLC.